Blood test developments offer new insights into lung cancer treatment

New findings from the NeoCOAST-2 trial suggest that blood tests measuring circulating tumor DNA (ctDNA) may help predict treatment outcomes for patients with operable non-small cell lung cancer. According to the analysis presented at the ESMO Congress 2026, patients whose ctDNA became undetectable during therapy were more likely to remain free of cancer-related events. This approach allows clinicians to assess treatment response before surgery, rather than waiting for post-surgical pathological results.

The NeoCOAST-2 study involved 202 randomized patients receiving combinations of immunotherapy, such as durvalumab, with chemotherapy and other agents like oleclumab, monalizumab, or datopotamab deruxtecan. The use of a tumor-agnostic ctDNA assay provides a molecular signal of response without requiring custom assays for every patient.

In a related context of lung cancer management, biomarker testing remains a critical step in determining effective therapies. In certain populations, such as those in India, approximately 30% to 40% of patients with non-small cell lung cancer possess specific genetic changes, such as EGFR or ALK mutations, that can be targeted with specific medications. These tests, typically performed on biopsy tissue or via blood samples, help doctors select targeted treatments over traditional chemotherapy.